Lynparza May Significantly Improve Outcomes for Ovarian Cancer Patients, Trial Shows

Lynparza May Significantly Improve Outcomes for Ovarian Cancer Patients, Trial Shows
Certain ovarian cancer patients with BRCA mutations may benefit from maintenance treatment with the PARP inhibitor Lynparza (olaparib). The therapy significantly increases progression-free survival, according to the results of a Phase 3 trial recently released by AstraZeneca. Lynparza was the first PARP inhibitor to be approved for patients with germline BRCA-mutated advanced ovarian cancer. It works by inducing damage in DNA molecules and is particularly effective in tumors that have DNA repair deficiencies, such as BRCA-mutated tumors. This allows the agent to preferentially kill cancer cells, leaving healthy cells with functional DNA repair pathways unharmed. The SOLO-2 Phase 3 trial (NCT01874353), a double-blind and placebo-controlled study, was designed to assess the effectiveness of Lynparza as a maintenance therapy in BRCA-positive ovarian cancer patients who were sensitive to platinum-based chemotherapy but relapsed following at least two prior lines of treatment. The study, conducted by the European Network for Gynaecological Oncological Trial Groups (ENGOT) and Groupe d'Investigateurs National pour l'Etude des Cancers de l'Ovaire et du sein (GINECO), enrolled 295 patients with BRCA1 or BRCA2 mutations who were randomized to receive either Lynparza tablets or a placebo until disease progression. Results revealed a significant clinical improvement in progression-free survival in the Lynparza arm compared to the placebo arm. The progression-free survival in the Lynparza arm was also substantially higher than in a prior Phase 2 trial (Study 19) that evalu
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *